Position in TNGX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$23,959,944
New position
Shares Held
766,473
first reported quarter
Ownership
0.455%
of shares outstanding
% of Portfolio
0.40%
of 13F equity value
Holder Rank
#45
of 247 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026SAMLYN CAPITAL, LLC holds $419,609,524 across 10 Biotechnology names. TNGX ranks #9 (5.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
732,568 | $78,106,398 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
246,015 | $60,217,090 | |
| 3 | RCUS |
Arcus Biosciences, Inc.
|
1,547,182 | $47,699,619 | |
| 4 | ELVN |
Enliven Therapeutics, Inc.
|
912,637 | $46,316,326 | |
| 5 | ERAS |
Erasca, Inc.
|
2,256,986 | $41,347,982 | |
| 6 | DYN |
Dyne Therapeutics, Inc.
|
1,754,708 | $38,972,063 | |
| 7 | SYRE |
Spyre Therapeutics, Inc.
|
400,075 | $35,518,657 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
151,290 | $28,333,589 |
All Filings in TNGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $23,959,944 | 766,473 | Shares | Defined | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||